SCHEMBL4978987

SCHEMBL4978987

CCn1cnc2c(=O)n(-c3ccc(F)cc3)c(CC(C)C(F)(F)F)nc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
HKDC1 Q2TB90 2/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
LMNA P02545 3/20 0.37
HPGD P15428 3/20 0.37
TSHR P16473 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CDK1 P06493 7/20 0.37
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4529554 0.91 DRD1 (0.41) NPC1LMNATSHRALDH1A1CDK1
SCHEMBL4529223 0.90 HKDC1 (0.40) SMN1; SMN2HKDC1NPC1RAB9ALMNA
SCHEMBL4977191 0.89 CTSS (0.39) NPC1ALDH1A1CDK1PDE4APDE4B
SCHEMBL4510793 0.88 HKDC1 (0.39) SMN1; SMN2HKDC1NPC1RAB9ALMNA
SCHEMBL4527001 0.88 SMN1; SMN2 (0.36) SMN1; SMN2HKDC1NPC1RAB9ALMNA
SCHEMBL4978421 0.86 SRC (0.33) SMN1; SMN2TSHRALDH1A1CDK1PDE4A
SCHEMBL4526037 0.84 NPC1 (0.44) SMN1; SMN2HKDC1NPC1RAB9ALMNA
SCHEMBL4520614 0.84 CNR1 (0.40) NPC1LMNAHPGDTSHRALDH1A1
SCHEMBL4522018 0.82 CNR1 (0.46) NPC1LMNATSHRALDH1A1
SCHEMBL4515817 0.82 LMNA (0.43) SMN1; SMN2HKDC1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US claimed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 SMN1; SMN2 3316/4885HKDC1 1725/4885NPC1 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.